Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial - PubMed
4 hours ago
- #cardiovascular risk
- #type 2 diabetes
- #semaglutide
- Oral semaglutide reduced major adverse cardiovascular events by 14% vs placebo in high-risk type 2 diabetes patients.
- The study analyzed changes in ASCVD risk factors, including HbA1c, body weight, blood pressure, and lipid levels.
- Early improvements were observed in HbA1c (-0.87%), body weight (-2.54%), systolic BP (-3.84 mm Hg), and lipid profiles with oral semaglutide.
- Sustained benefits were seen over the trial duration, with significant reductions in HbA1c, body weight, and systolic BP at week 156.
- No significant differences were found for LDL cholesterol or diastolic BP between oral semaglutide and placebo.